Advertisement

The efficacy of anti-CD19 chimeric antigen receptor T cells for B-cell malignancies

      Abstract

      Immunotherapy with chimeric antigen receptor T (CAR-T) cells has proved remarkably effective in recently published clinical trials. In this meta-analysis, we performed a systematic review in terms of the clinical response treated with CAR-T cells in acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL) and lymphomas patients. Thirty-eight published clinical studies including 665 patients were eligible for response rate (RR) evaluation. The overall pooled RR of CD19-CAR-T cells was 72% (95% confidence interval: 62–77%). The various clinical parameters were analyzed. RR was 81% in ALL, 68% in lymphoma and 70% in CLL. RR in patients who received interleukin (IL)-2 was 70%, whereas in those who did not receive IL-2, it was 74%. RR was 75% with lymphodepletion and 56% without lymphodepletion. RR with autologous cells was 76% and 57% with allogeneic cells. In conclusion, this meta-analysis showed a high clinical RR of CD19-CAR-T cell–based immunotherapy in patients with refractory B-cell malignancies.

      Key Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Cytotherapy
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • McCreedy B.J.
        • Senyukov V.V.
        • Nguyen K.T.
        Off the shelf T cell therapies for hematologic malignancies.
        Best Pract Res Clin Haematol. 2018; 31 (Epub 2018 Mar 28): 166-175https://doi.org/10.1016/j.beha.2018.03.001
        • Lichtman E.I.
        • Dotti G.
        Chimeric antigen receptor T-cells for B-cell malignancies.
        Transl Res. 2017; 187 (Epub 2017 Jun 29): 59-82https://doi.org/10.1016/j.trsl.2017.06.011
        • Tasian S.K.
        • Gardner R.A.
        CD19-redirected chimeric antigen receptor-modified T cells: a promising immunotherapy for children and adults with B-cell acute lymphoblastic leukemia (ALL).
        Ther Adv Hematol. 2015; 6: 228-241https://doi.org/10.1177/2040620715588916
        • Park J.H.
        • Geyer M.B.
        • Brentjens R.J.
        CD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date.
        Blood. 2016; 127 (Epub 2016 May 20): 3312-3320https://doi.org/10.1182/blood-2016-02-629063
        • Tran E.
        • Longo D.L.
        • Urba W.J.
        A Milestone for CAR T Cells.
        N Engl J Med. 2017; 377 (Epub 2017 Dec 10): 2593-2596https://doi.org/10.1056/NEJMe1714680
        • Maude S.L.
        • Laetsch T.W.
        • Buechner J.
        • Rives S.
        • Boyer M.
        • Bittencourt H.
        • et al.
        Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia.
        N Engl J Med. 2018; 378: 439-448https://doi.org/10.1056/NEJMoa1709866
        • Neelapu S.S.
        • Locke F.L.
        • Bartlett N.L.
        • Lekakis L.J.
        • Miklos D.B.
        • Jacobson C.A.
        • et al.
        Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma.
        N Engl J Med. 2017; 377 (Epub 2017 Dec 10): 2531-2544https://doi.org/10.1056/NEJMoa1707447
        • Siddiqi T.
        • Abramson J.S.
        • Palomba M.L.
        • Gordon L.I.
        • Lunning M.A.
        Correlation of patient characteristics and biomarkers with clinical outcomes of JCAR017 in R/R aggressive B-NHL (TRANSCEND NHL 001 study).
        Journal of Clinical Oncology. 2018; 36 (122-122)
        • Xu X.J.
        • Zhao H.Z.
        • Tang Y.M.
        Efficacy and safety of adoptive immunotherapy using anti-CD19 chimeric antigen receptor transduced T-cells: a systematic review of phase I clinical trials.
        Leuk Lymphoma. 2013; 54 (Epub 2012 Sep 8): 255-260https://doi.org/10.3109/10428194.2012.715350
        • Zhu Y.
        • Tan Y.
        • Ou R.
        • Zhong Q.
        • Zheng L.
        • Du Y.
        • et al.
        Anti-CD19 chimeric antigen receptor-modified T cells for B-cell malignancies: a systematic review of efficacy and safety in clinical trials.
        Eur J Haematol. 2016; 96 (Epub 2015 Jul 3): 389-396https://doi.org/10.1111/ejh.12602
        • Zhang T.
        • Cao L.
        • Xie J.
        • Shi N.
        • Zhang Z.
        • Luo Z.
        • et al.
        Efficiency of CD19 chimeric antigen receptor-modified T cells for treatment of B cell malignancies in phase I clinical trials: a meta-analysis.
        Oncotarget. 2015; 6: 33961-33971https://doi.org/10.18632/oncotarget.5582
        • Riaz I.B.
        • Zahid U.
        • Kamal M.U.
        • Husnain M.
        • McBride A.
        • Hua A.
        • et al.
        Anti-CD 19 and anti-CD 20 CAR-modified T cells for B-cell malignancies: a systematic review and meta-analysis.
        Immunotherapy. 2017; 9: 979-993https://doi.org/10.2217/imt-2017-0062
        • Hao L.
        • Li T.
        • Chang L.J.
        • Chen X.
        Adoptive immunotherapy for B-cell malignancies using CD19-targeted chimeric antigen receptor T-cells: A systematic review of efficacy and safety.
        Curr Med Chem. 2017; ([Epub ahead of print])https://doi.org/10.2174/0929867324666170801101842
        • Jin Z.
        • Xiang R.
        • Qing K.
        • Li X.
        • Zhang Y.
        • Wang L.
        • et al.
        The severe cytokine release syndrome in phase I trials of CD19-CAR-T cell therapy: a systematic review.
        Ann Hematol. 2018; ([Epub ahead of print])https://doi.org/10.1007/s00277-018-3368-8
        • Vormittag P.
        • Gunn R.
        • Ghorashian S.
        • Veraitch F.S.
        A guide to manufacturing CAR T cell therapies.
        Curr Opin Biotechnol. 2018; 53 (Epub 2018 Feb 18): 164-181https://doi.org/10.1016/j.copbio.2018.01.025
        • Sharma P.
        • King G.T.
        • Shinde S.S.
        • Purev E.
        • Jimeno A.
        Axicabtagene ciloleucel for the treatment of relapsed/refractory B-cell non-Hodgkin's lymphomas.
        Drugs Today (Barc). 2018; 54: 187-198https://doi.org/10.1358/dot.2018.54.3.2776625
        • Jensen M.C.
        • Popplewell L.
        • Cooper L.J.
        • DiGiusto D.
        • Kalos M.
        • Ostberg J.R.
        • Forman S.J.
        Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans.
        Biol Blood Marrow Transplant. 2010; 16 (Epub 2010 Mar 19): 1245-1256https://doi.org/10.1016/j.bbmt.2010.03.014
        • Kochenderfer J.N.
        • Dudley M.E.
        • Kassim S.H.
        • Somerville R.P.
        • Carpenter R.O.
        • Stetler-Stevenson M.
        • et al.
        Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor.
        J Clin Oncol. 2015; 33 (Epub 2014 Aug 25): 540-549https://doi.org/10.1200/JCO.2014.56.2025
        • Kochenderfer J.N.
        • Wilson W.H.
        • Janik J.E.
        • Dudley M.E.
        • Stetler-Stevenson M.
        • Feldman S.A.
        • et al.
        Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19.
        Blood. 2010; 116 (Epub 2010 Jul 28): 4099-4102https://doi.org/10.1182/blood-2010-04-281931
        • Kochenderfer J.N.
        • Dudley M.E.
        • Carpenter R.O.
        • Kassim S.H.
        • Rose J.J.
        • Telford W.G.
        • et al.
        Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation.
        Blood. 2013; 122 (Epub 2013 Sep 20): 4129-4139https://doi.org/10.1182/blood-2013-08-519413
        • Kochenderfer J.N.
        • Dudley M.E.
        • Feldman S.A.
        • Wilson W.H.
        • Spaner D.E.
        • Maric I.
        • et al.
        B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells.
        Blood. 2012; 119 (Epub 2011 Dec 8): 2709-2720https://doi.org/10.1182/blood-2011-10-384388
        • Brentjens R.J.
        • Rivière I.
        • Park J.H.
        • Davila M.L.
        • Wang X.
        • Stefanski J.
        • et al.
        Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias.
        Blood. 2011; 118 (Epub 2011 Aug 17): 4817-4828https://doi.org/10.1182/blood-2011-04-348540
        • Kalos M.
        • Levine B.L.
        • Porter D.L.
        • Katz S.
        • Grupp S.A.
        • Bagg A.
        • June C.H.
        T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia.
        Sci Transl Med. 2011; 3: 95ra73https://doi.org/10.1126/scitranslmed.3002842
        • Savoldo B.
        • Ramos C.A.
        • Liu E.
        • Mims M.P.
        • Keating M.J.
        • Carrum G.
        • et al.
        CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients.
        J Clin Invest. 2011; 121 (Epub 2011 Apr 11): 1822-1826https://doi.org/10.1172/JCI46110
        • Brentjens R.J.
        • Davila M.L.
        • Riviere I.
        • Park J.
        • Wang X.
        • Cowell L.G.
        • et al.
        CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia.
        Sci Transl Med. 2013; 5: 177ra38https://doi.org/10.1126/scitranslmed.3005930
        • Grupp S.A.
        • Kalos M.
        • Barrett D.
        • Aplenc R.
        • Porter D.L.
        • Rheingold S.R.
        • Teachey D.T.
        • Chew A.
        • Hauck B.
        • Wright J.F.
        • Milone M.C.
        • Levine B.L.
        • June C.H.
        Chimeric antigen receptor-modified T cells for acute lymphoid leukemia.
        N Engl J Med. 2013; 368 (Epub 2013 Mar 25): 1509-1518https://doi.org/10.1056/NEJMoa1215134
        • Davila M.L.
        • Riviere I.
        • Wang X.
        • Bartido S.
        • Park J.
        • Curran K.
        • et al.
        Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia.
        Sci Transl Med. 2014; 6: 224ra25https://doi.org/10.1126/scitranslmed.3008226
        • Lee D.W.
        • Kochenderfer J.N.
        • Stetler-Stevenson M.
        • YK 1, Cui
        • Delbrook C.
        • Feldman S.A.
        • et al.
        T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial.
        Lancet. 2015; 385 (Epub 2014 Oct 13): 517-528https://doi.org/10.1016/S0140-6736(14)61403-3
        • Maude S.L.
        • Frey N.
        • Shaw P.A.
        • Aplenc R.
        • Barrett D.M.
        • Bunin N.J.
        • et al.
        Chimeric antigen receptor T cells for sustained remissions in leukemia.
        N Engl J Med. 2014 Oct 16; 371: 1507-1517https://doi.org/10.1056/NEJMoa1407222
        • Cruz C.R.
        • Micklethwaite K.P.
        • Savoldo B.
        • Ramos C.A.
        • Lam S.
        • Ku S.
        • et al.
        Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study.
        Blood. 2013; 122 (Epub 2013 Sep 12): 2965-2973https://doi.org/10.1182/blood-2013-06-506741
        • Porter D.L.
        • Levine B.L.
        • Kalos M.
        • Bagg A.
        • June C.H.
        Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia.
        N Engl J Med. 2011 Aug 25; 365 (Epub 2011 Aug 10): 725-733https://doi.org/10.1056/NEJMoa1103849
        • Gardner R.
        • Wu D.
        • Cherian S.
        • Fang M.
        • Hanafi L.A.
        • Finney O.
        • et al.
        Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy.
        Blood. 2016; 127 (Epub 2016 Feb 23): 2406-2410https://doi.org/10.1182/blood-2015-08-665547
        • Kebriaei P.
        • Singh H.
        • Huls M.H.
        • Figliola M.J.
        • Bassett R.
        • Olivares S.
        • et al.
        Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells.
        J Clin Invest. 2016; 126 (Epub 2016 Aug 2): 3363-3376https://doi.org/10.1172/JCI86721
        • Brudno J.N.
        • Somerville R.P.
        • Shi V.
        • Rose J.J.
        • Halverson D.C.
        • Fowler D.H.
        • et al.
        Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease.
        J Clin Oncol. 2016; 34 (Epub 2016 Jan 25): 1112-1121https://doi.org/10.1200/JCO.2015.64.5929
        • Dai H.
        • Zhang W.
        • Li X.
        • Han Q.
        • Guo Y.
        • Zhang Y.
        • et al.
        Tolerance and efficacy of autologous or donor-derived T cells expressing CD19 chimeric antigen receptors in adult B-ALL with extramedullary leukemia.
        Oncoimmunology. 2015; 4 (eCollection 2015 Nov)e1027469
        • Garfall A.L.
        • Maus M.V.
        • Hwang W.T.
        • Lacey S.F.
        • Mahnke Y.D.
        • Melenhorst J.J.
        • et al.
        Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma.
        N Engl J Med. 2015; 373: 1040-1047https://doi.org/10.1056/NEJMoa1504542
        • Fraietta J.A.
        • Beckwith K.A.
        • Patel P.R.
        • Ruella M.
        • Zheng Z.
        • Barrett D.M.
        • et al.
        Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia.
        Blood. 2016; 127 (Epub 2016 Jan 26): 1117-1127https://doi.org/10.1182/blood-2015-11-679134
        • Turtle C.J.
        • Hanafi L.A.
        • Berger C.
        • Gooley T.A.
        • Cherian S.
        • Hudecek M.
        • et al.
        CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients.
        J Clin Invest. 2016; 126 (Epub 2016 Apr 25): 2123-2138https://doi.org/10.1172/JCI85309
        • Bhoj V.G.
        • Arhontoulis D.
        • Wertheim G.
        • Capobianchi J.
        • Callahan C.A.
        • Ellebrecht C.T.
        • et al.
        Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapy.
        Blood. 2016; 128 (Epub 2016 May 10): 360-370https://doi.org/10.1182/blood-2016-01-694356
        • Porter D.L.
        • Hwang W.T.
        • Frey N.V.
        • Lacey S.F.
        • Shaw P.A.
        • Loren A.W.
        • et al.
        Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia.
        Sci Transl Med. 2015; 7: 303ra139https://doi.org/10.1126/scitranslmed.aac5415
        • Hu Y.
        • Wu Z.
        • Luo Y.
        • Shi J.
        • Yu J.
        • Pu C.
        • et al.
        Potent Anti-leukemia Activities of Chimeric Antigen Receptor-Modified T Cells against CD19 in Chinese Patients with Relapsed/Refractory Acute Lymphocytic Leukemia.
        Clin Cancer Res. 2017; 23 (Epub 2016 Dec 30): 3297-3306https://doi.org/10.1158/1078-0432.CCR-16-1799
        • Turtle C.J.
        • Haafi L.A.
        • Berger C.
        • Hudecek M.
        • Pender B.
        • Robinson E.
        • et al.
        Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells.
        Sci Transl Med. 2016; 8: 355ra116https://doi.org/10.1126/scitranslmed.aaf8621
        • Wang X.
        • Popplewell L.L.
        • Wagner J.R.
        • Naranjo A.
        • Blanchard M.S.
        • Mott M.R.
        • et al.
        Phase 1 studies of central memory-derived CD19 CAR T-cell therapy following autologous HSCT in patients with B-cell NHL.
        Blood. 2016; 127 (Epub 2016 Apr 26): 2980-2990https://doi.org/10.1182/blood-2015-12-686725
        • Kochenderfer J.N.
        • Somerville R.P.T.
        • Lu T.
        • Shi V.
        • Bot A.
        • Rossi J.
        • et al.
        Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 Levels.
        J Clin Oncol. 2017; 35 (Epub 2017 Mar 14): 1803-1813https://doi.org/10.1200/JCO.2016.71.3024
        • Locke F.L.
        • Neelapu S.S.
        • Bartlett N.L.
        • Siddiqi T.
        • Chavez J.C.
        • Hosing C.M.
        • et al.
        Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma.
        Mol Ther. 2017; 25 (Epub 2017 Jan 4): 285-295https://doi.org/10.1016/j.ymthe.2016.10.020
        • Chen Y.
        • Cheng Y.
        • Suo P.
        • Yan C.
        • Wang Y.
        • Chen Y.
        • et al.
        Donor-derived CD19-targeted T cell infusion induces minimal residual disease-negative remission in relapsed B-cell acute lymphoblastic leukaemia with no response to donor lymphocyte infusions after haploidentical haematopoietic stem cell transplantation.
        Br J Haematol. 2017; 179 (Epub 2017 Oct 26): 598-605https://doi.org/10.1111/bjh.14923
        • Cheng Z.
        • Wei R.
        • Ma Q.
        • Shi L.
        • He F.
        • Shi Z.
        • et al.
        In Vivo Expansion and Antitumor Activity of Coinfused CD28- and 4-1BB-Engineered CAR-T Cells in Patients with B Cell Leukemia.
        Mol Ther. 2018; 26 (Epub 2018 Feb 2): 976-985https://doi.org/10.1016/j.ymthe.2018.01.022
        • Cao J.
        • Wang G.
        • Cheng H.
        • Wei C.
        • Qi K.
        • Sang W.
        • et al.
        Potent anti-leukemia activities of humanized CD19-targeted Chimeric antigen receptor T (CAR-T) cells in patients with relapsed/refractory acute lymphoblastic leukemia.
        Am J Hematol. 2018; 93 (Epub 2018 Apr 28): 851-858https://doi.org/10.1002/ajh.25108
        • Schuster S.J.
        • Svoboda J.
        • Chong E.A.
        • Nasta S.D.
        • Mato A.R.
        • Anak Ö.
        • et al.
        Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas.
        N Engl J Med. 2017; 377 (Epub 2017 Dec 10): 2545-2554https://doi.org/10.1056/NEJMoa1708566
        • Park J.H.
        • Rivière I.
        • Gonen M.
        • Wang X.
        • Sénéchal B.
        • Curran K.J.
        • et al.
        Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia.
        N Engl J Med. 2018; 378: 449-459https://doi.org/10.1056/NEJMoa1709919
        • Neelapu S.S.
        • Locke F.L.
        • Bartlett N.L.
        • Lekakis L.J.
        • Miklos D.B.
        • Jacobson C.A.
        • et al.
        Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma.
        N Engl J Med. 2017; 377 (Epub 2017 Dec 10): 2531-2544https://doi.org/10.1056/NEJMoa1707447
        • Wei G.
        • Hu Y.
        • Pu C.
        • Yu J.
        • Luo Y.
        • Shi J.
        • et al.
        CD19 targeted CAR-T therapy versus chemotherapy in re-induction treatment of refractory/relapsed acute lymphoblastic leukemia: results of a case-controlled study.
        Ann Hematol. 2018; 97 (Epub 2018 Feb 7): 781-789https://doi.org/10.1007/s00277-018-3246-4
        • Gardner R.A.
        • Finney O.
        • Annesley C.
        • Brakke H.
        • Summers C.
        • Leger K.
        • et al.
        Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults.
        Blood. 2017; 129 (Epub 2017 Apr 13): 3322-3331https://doi.org/10.1182/blood-2017-02-769208
        • Turtle C.J.
        • Hay K.A.
        • Hanafi L.A.
        • Li D.
        • Cherian S.
        • Chen X.
        • Wood B.
        • Lozanski A.
        • Byrd J.C.
        • Heimfeld S.
        • Riddell S.R.
        • Maloney D.G.
        Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib.
        J Clin Oncol. 2017; 35 (Epub 2017 Jul 17): 3010-3020https://doi.org/10.1200/JCO.2017.72.8519
        • Zhou H.
        • Luo Y.
        • Zhu S.
        • Wang X.
        • Zhao Y.
        • Ou X.
        • et al.
        The efficacy and safety of anti-CD19/CD20 chimeric antigen receptor- T cells immunotherapy in relapsed or refractory B-cell malignancies:a meta-analysis.
        BMC Cancer. 2018; 18: 929https://doi.org/10.1186/s12885-018-4817-4
        • Rosenberg S.A.
        • Restifo N.P.
        Adoptive cell transfer as personalized immunotherapy for human cancer.
        Science. 2015; 348: 62-68https://doi.org/10.1126/science.aaa4967
        • Brudno J.N.
        • Kochenderfer J.N.
        Chimeric antigen receptor T-cell therapies for lymphoma.
        Nat Rev Clin Oncol. 2018; 15 (Epub 2017 Aug 31): 31-46https://doi.org/10.1038/nrclinonc.2017.128
        • Anwer F.
        • Shaukat A.A.
        • Zahid U.
        • Husnain M.
        • McBride A.
        • Persky D.
        • et al.
        Donor origin CAR T cells: graft versus malignancy effect without GVHD, a systematic review.
        Immunotherapy. 2017; 9: 123-130https://doi.org/10.2217/imt-2016-0127